Tesamorelin protocol: Frequently asked questions

Resume at your scheduled dose the next evening—do not double-dose. Missing 48 hours interrupts the pulsatile GH restoration pattern but doesn't require dose escalation or restart. Patients who miss more than two doses per month show 35–40% slower VAT reduction compared to those with perfect adherence, because the mechanism depends on sustained daily GHRH receptor stimulation to maintain elevated GH pulse amplitude. If adherence is consistently difficult, switching to CJC-1295 with DAC (weekly injection) may be a better protocol fit despite the loss of physiological pulsatility.

This occurs in 8–12% of patients and is typically transient. GH acutely impairs peripheral glucose uptake through direct antagonism of insulin signaling in skeletal muscle—this effect reverses as visceral fat mobilization improves hepatic insulin sensitivity by week 8–12. Monitor fasting glucose weekly during the first month; if it rises above 110 mg/dL and remains elevated beyond week 6, reduce the dose to 1mg daily until glucose stabilizes. Patients with baseline HbA1c >6.5% should have more frequent glucose monitoring and may require temporary adjustment of metformin or other glucose-lowering agents during the titration phase.

Rotate injection sites systematically—abdomen (rotating quadrants), anterior thighs, and upper buttocks. Injection site erythema or mild induration occurs in 20–30% of users but typically resolves within two weeks as local immune tolerance develops. If reactions persist beyond four weeks or worsen (nodules >1 cm, warmth, drainage), this suggests either peptide contamination or an excipient sensitivity. Switch to a different manufacturer or compounding pharmacy—tesamorelin formulations vary in excipient composition (mannitol content, pH buffering), and some patients tolerate one source better than another. As a last resort, ipamorelin (a ghrelin mimetic with similar but milder GH-stimulating effects) can substitute, though VAT reduction is typically 30–40% less pronounced.

Reduce the dose by 0.5mg and maintain that lower dose for 4 weeks. Joint pain related to IGF-1 elevation is usually dose-dependent and reversible. If pain persists at the reduced dose, discontinue the protocol for 2 weeks to allow IGF-1 levels to normalize, then restart at 0.5mg daily. Chronic joint pain despite dose reduction suggests an underlying condition unrelated to tesamorelin. Consult with a prescribing physician before resuming therapy.

Hold the current dose and recheck glucose in 2 weeks. If it normalizes, resume the protocol at the same dose. If it remains elevated, reduce the dose by 50% (from 1mg to 0.5mg, or from 1.5mg to 0.75mg) and reassess glucose after another 2 weeks. Persistent hyperglycemia despite dose reduction is a contraindication for continued use. Growth hormone's counter-regulatory effect on insulin is a core mechanism, not a side effect that resolves with time.

Yes, metformin and tesamorelin are frequently used together in the 50+ age group. Metformin improves hepatic insulin sensitivity, which partially offsets growth hormone's counter-regulatory effect on glucose. Start at 1mg daily tesamorelin with close glucose monitoring at weeks 2, 4, and 8. If fasting glucose increases by more than 10 mg/dL despite metformin, reduce the tesamorelin dose rather than increasing metformin. The goal is metabolic balance, not forcing both medications to maximum doses.

Increase the dose to 1.5mg daily and recheck IGF-1 at week 8. If IGF-1 elevation remains minimal (less than 30 ng/mL from baseline), the limitation is hepatic receptor capacity, not peptide dose. Further dose increases are unlikely to help and may increase side effect risk without additional benefit. At that point, optimize thyroid function if TSH is elevated, improve insulin sensitivity with lifestyle modification or metformin, and consider whether the modest IGF-1 response you're achieving justifies continued therapy.

Transient hyperglycemia. A 5-10 mg/dL increase in fasting glucose. Is common in weeks 1-4 as GH increases hepatic glucose output. This normalizes by week 6-8 as insulin sensitivity improves and visceral fat decreases. If fasting glucose rises above 110 mg/dL or doesn't resolve by week 8, reduce the dose to 0.5mg nightly for two weeks before escalating back to 1mg. Men with pre-existing type 2 diabetes should monitor glucose closely and may require metformin co-administration.

First, verify injection timing and reconstitution protocol. Most efficacy failures trace to improper storage or daytime administration. Second, confirm you're measuring visceral fat, not total body fat. Tesamorelin doesn't reduce subcutaneous fat, so scale weight and limb measurements won't change dramatically. A DEXA scan or CT visceral fat measurement at week 8 is the gold standard. If VAT hasn't decreased at all by week 10, the peptide may be degraded, the dose may be insufficient, or pituitary responsiveness may be impaired.

Yes, tesamorelin works independently of testosterone pathways. TRT addresses androgen deficiency but doesn't reverse visceral fat accumulation or restore growth hormone pulsatility. Combining TRT with tesamorelin targets both hormonal deficits simultaneously. Clinical data shows men on stable TRT who add tesamorelin achieve the same 10-15% VAT reduction as those not on TRT. The peptides work through separate receptor systems with no negative interaction.

Reduce dose to 1 mg daily immediately and recheck IGF-1 in 4 weeks. Sustained supraphysiologic IGF-1 increases glucose dysregulation risk and causes joint pain in weight-bearing joints. If IGF-1 normalizes at 1 mg, continue at that dose rather than returning to 2 mg. VAT reduction continues at the lower dose, just at a slower rate (8–12% over 26 weeks instead of 15–18%). The clinical decision hinges on whether the patient prioritizes speed of VAT reduction or minimizing adverse events.

Missing 2-3 doses per week significantly reduces cumulative GH exposure and blunts fat loss results. If you miss a single dose, resume the next night. Do not double-dose. If you miss an entire week, the protocol isn't ruined, but expect slower progress. Tesamorelin's effect is cumulative and dose-dependent; consistency matters more than perfection. Missing more than 30% of doses across the 16-week protocol typically results in VAT reduction below 7-8%, roughly half the expected outcome.

This is somatotroph desensitization. The pituitary is releasing less GH per pulse even though IGF-1 hasn't dropped yet. Two protocol adjustments work: (1) dose cycling (2 mg for 5 days, none for 2 days) restores receptor sensitivity by allowing GHRH receptor downregulation to reverse during off days; (2) temporary dose reduction to 1 mg for 4 weeks followed by return to 2 mg. Cycling is more effective if initiated proactively at week 16 rather than waiting until week 24 when VAT reduction has fully stalled.

Rotate injection sites more aggressively. Most severe reactions occur when patients inject the same anatomical area (abdomen, thigh) more than twice per week. Switch to a 5-site rotation: left abdomen, right abdomen, left lateral thigh, right lateral thigh, buttocks. If reactions persist despite rotation, evaluate for hypersensitivity to the excipient (mannitol or trehalose in most formulations). Compounded tesamorelin from a different 503B facility with an alternative excipient may resolve the issue. Verify formulation details before switching.